NLRP3 and Hepatic steatosis: Nlrp3-deficient animals are protected from obesity-associated hepatic steatosis, adipose tissue inflammation, and glucose intolerance, supporting the notion that the effects of ceramides on NLRP3-dependent pathways may be relevant in the etiology of these metabolic disorders [147].